Clinical Trial VICCHN0603
Title
Effect of PI3K Inhibition in HPV Infected Cell (deidentified)
Principal Investigator(s)
Details
- Protocol No. VICCHN0603
- Open Date: 04/28/2006
- Staging: NA
- Age Group: Adults
- Scope: Local
- Objective: Analyses of HPV(+) and HPV(-) for PIK3CA mutations and amplification and expression of p100a PIK3CA can be activated by overexpression, amplification or mutation. To analyze the PIK3CA gene for mutation and amplification and determine protein expression in 20 HPV(+) and 20 HPV(-) oropharyngeal HNSCC
- Disease Sites: Head/Neck
- Therapies: Correlative
- Drugs: None Specified
- Participating Institutions: Veterans Administration; Vanderbilt University
- National Clinical Trial ID: NCT00897988
- Secondary Protocol No: Not Specified
Description
None Provided.
Eligibility
| Ages Eligible for Study: | N/A and older |
|---|---|
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
DISEASE CHARACTERISTICS:
• Undergoing operative procedures for biopsy and/or resection of squamous cell carcinoma (SCC) of the oropharynx
• Tumor tissue sample available from the Head and Neck Tissue Repository and Clinical Database of Vanderbilt University
• No tumors with human papilloma virus (HPV) DNA sequences but no expression of E6
PATIENT CHARACTERISTICS:
• See Disease Characteristics
PRIOR CONCURRENT THERAPY:
• Not specified
Learn More
- Call toll-free number: 1-800-811-8480
- Use our Online self–referral form
- Print this page for your doctor
You do not have JavaScript enabled. This site works better with JavaScript turned on.
